On May 22, the world authoritative medical journal “The Lancet” published the clinical data results of the new crown vaccine human trials of the team of Academician Chen Wei of the Academy of Military Medicine and Professor Zhu Fengcai of the Jiangsu Provincial Center for Disease Control. All 108 volunteers in the clinical phase have a significant cellular immune response, which is the human clinical data of the world’s first new crown vaccine.

The latest research shows that this is the first COVID-19 vaccine to enter the first phase of clinical trials. It is safe and well tolerated, and can produce anti-SARS- in humans. CoV-2 immune response. An open-label test conducted in 108 healthy adults showed promising results after 28 days. The final result will be evaluated within 6 months, and further tests are needed to determine whether the immune response it causes can be Effectively prevent SARS-CoV-2 infection.

In the information provided by The Lancet, Chen Wei of the Institute of Bioengineering, Academy of Military Medical Sciences, responsible for this research, said that this is a milestone. “The experiment showed that a single dose of the new type 5 adenovirus vector COVID-19 (Ad5-nCoV) vaccine can produce virus-specific antibodies and T cells within 14 days, making it possible for further research.” Chen Wei said, “However, these results should be interpreted with caution. The challenge of developing the COVD-19 vaccine is unprecedented, and the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from COVID-19. This result shows Hope for the development of the COVID-19 vaccine, but there is still a long way to go before everyone can use this vaccine. “

Effective vaccines are considered A long-term solution to control the COVID-19 pandemic. Currently, there are more than 100 candidate COVID-19 vaccine candidates under development worldwide. The new Ad5 carrier COVID-19 vaccine evaluated in this trial was tested in humans for the first time.

It uses a weakened common cold virus (adenovirus, which easily infects human cells, but cannot cause disease) to encode the inheritance of the SARS-CoV-2 spike protein The substance is passed to the cell. These cells then produce spike proteins and reach the lymph nodes. In the immune system, the lymph nodes produce antibodies that recognize the spike proteins and fight the coronavirus.

“Our study found that pre-existing Ad5 immunization can slow down the rapid immune response to SARS-CoV-2 and reduce the peak level of response. In addition, high Existing Ad5 immunity is also availableIt can have a negative impact on the sustainability of the immune response caused by the vaccine. “Professor Zhu Fengcai of Jiangsu Provincial Center for Disease Control and Prevention said.

Researchers pointed out that the main limitation of the trial is its small sample size, relatively short duration and lack of randomness The control group, which limits the ability to produce more rare adverse reactions to the vaccine or provides strong evidence for its ability to produce anti-inflammatory drugs. Before everyone can use the trial vaccine, further research is required.
< div class = "contheight"> At present, a randomized, double-blind, placebo-controlled phase 2 clinical trial of Ad5-nCoV vaccine has been initiated in Wuhan to determine whether the results can be replicated.

(Health Times reporter Wei Chuannan and Hao Qianyu compiled based on the information provided by The Lancet. The original title is “Heavy! Academician Chen Wei ’s New Crown Vaccine Clinical Trial Results Release: All Immune Answer! “)